Xilio Therapeutics (XLO) Non Operating Income (2020 - 2026)

Xilio Therapeutics has disclosed Non Operating Income across 7 years of filings, most recently posting $4.6 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at $4.6 million, up 682.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.3 million (down 490.92% YoY), and the FY2025 annual result was $1.1 million, down 52.97% from the prior year.
• Non Operating Income came in at $4.6 million for Q1 2026 at Xilio Therapeutics, up from $921000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $4.6 million in Q1 2026 to a low of -$14.4 million in Q3 2025.
• The 5-year median for Non Operating Income is $586000.0 (2025), against an average of -$220529.4.
• Across the five-year window, Non Operating Income jumped 1347.54% in 2023 and plunged 2035.04% in 2025, its largest moves.
• Xilio Therapeutics' Non Operating Income stood at $701000.0 in 2022, then slumped by 32.24% to $475000.0 in 2023, then climbed by 12.84% to $536000.0 in 2024, then jumped by 71.83% to $921000.0 in 2025, then soared by 397.61% to $4.6 million in 2026.
• The last three Non Operating Income figures came in at $4.6 million (Q1 2026), $921000.0 (Q4 2025), and -$14.4 million (Q3 2025), per Business Quant data.